Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer

References

• Koos D, Josephs SF, Alexandrescu DT, Chan RC, Ramos F, Bogin V, Gammil V, Dasanu CA, De Necochea-Campion R, Riordan NH, et al. Tumor vaccines in 2010: need for integration. Cell Immunol 2010; 263(2):138-47; PMID:20434139; http://dx.doi.org/10.1016/j.cellimm.2010.03.019
   PubMed Web of Science ®Google Scholar
• Baitsch L, Fuertes-Marraco SA, Legat A, Meyer C, Speiser DE. The three main stumbling blocks for anticancer T cells. Trends Immunol 2012; 33:364-72; PMID:22445288; http://dx.doi.org/10.1016/j.it.2012.02.006
   PubMed Web of Science ®Google Scholar
• Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007; 450:903-7; PMID:18026089; http://dx.doi.org/10.1038/nature06309
   PubMed Web of Science ®Google Scholar
• O'Sullivan T, Saddawi-Konefka R, Vermi W, Koebel CM, Arthur C, White JM, Uppaluri R, Andrews DM, Ngiow SF, Teng MW et al. Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med 2012; 209:1869-82; PMID:22927549; http://dx.doi.org/10.1084/jem.20112738
   PubMed Web of Science ®Google Scholar
• Dranoff G. Experimental mouse tumour models: what can be learnt about human cancer immunology?. Nat Rev Immunol 2011; 12:61-6; PMID:22134155
   PubMed Web of Science ®Google Scholar
• Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO, Green AL. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011; 29:1949-55; PMID:21483002; http://dx.doi.org/10.1200/JCO.2010.30.5037
   PubMed Web of Science ®Google Scholar
• Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: are we there yet?. Immunol Rev 2011; 239:27-44; PMID:21198663; http://dx.doi.org/10.1111/j.1600-065X.2010.00979.x
   PubMed Web of Science ®Google Scholar
• Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol 2011; 29:4828-36; PMID:22042955; http://dx.doi.org/10.1200/JCO.2011.38.0899
   PubMed Web of Science ®Google Scholar
• Kottke T, Errington F, Pulido J, Galivo F, Thompson J, Wongthida P, Diaz RM, Chong H, Ilett E, Chester J, et al. Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nat Med 2011; 17:854-9; PMID:21685898; http://dx.doi.org/10.1038/nm.2390
   PubMed Web of Science ®Google Scholar
• Willers J, Capone G, Lucchese A. Peptides: an arrival point in cancer vaccinology. Front Biosci 2012; 4:1381-92; PMID:22652880; http://dx.doi.org/10.2741/S340
   PubMedGoogle Scholar
• Yamada A, Sasada T, Noguchi M, Itoh K. Next-generation peptide vaccines for advanced cancer. Cancer Sci 2013; 104:15-21; PMID:23107418; http://dx.doi.org/10.1111/cas.12050
   PubMed Web of Science ®Google Scholar
• Burchill MA, Tamburini BA, Pennock ND, White JT, Kurche JS, Kedl RM. T cell vaccinology: exploring the known unknowns. Vaccine 2013; 31:297-305; PMID:23137843; http://dx.doi.org/10.1016/j.vaccine.2012.10.096
   PubMed Web of Science ®Google Scholar
• Bernatchez C, Zhu K, Li Y, Andersson H, Ionnides C, Fernandez-Viña M, Cano P, Copper L, Abbruzzese J, Hwu P, et al. Altered decamer and nonamer from an HLA-A0201-restricted epitope of surviving differentially stimulate T-cell responses in different individuals. Vaccine 2011; 29:3021-30; PMID:21320548; http://dx.doi.org/10.1016/j.vaccine.2011.01.115
   PubMed Web of Science ®Google Scholar
• Jordan KR, Buhrman JD, Sprague J, Moore BL, Gao D, Kappler JW, Slansky JE. TCR hypervariable regions expressed by T cells that respond to effective tumor vaccines. Cancer Immunol Immunother 2012; 61:1627-38; PMID:22350070; http://dx.doi.org/10.1007/s00262-012-1217-5
   PubMed Web of Science ®Google Scholar
• Abdul-Alim CS, Li Y, Yee C. Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses. J Immunol 2010; 184:6514-21; PMID:20483791; http://dx.doi.org/10.4049/jimmunol.0900448
   PubMed Web of Science ®Google Scholar
• Douat-Casassus C, Marchand-Geneste N, Diez E, Gervois N, Jotereau F, Quideau S. Synthetic anticancer vaccine candidates: rational design of antigenic peptide mimetics that activate tumor-specific T-cells. J Med Chem. 2007; 50:1598-609; PMID:17328535; http://dx.doi.org/10.1021/jm0613368
   PubMed Web of Science ®Google Scholar
• Neumann A, Hörzer H, Hillen N, Klingel K, Schmid-Horch B, Bühring HJ, Rammensee HG, Aebert H, Stevanovic S. Identification of HLA ligands and T-cell epitopes for immunotherapy of lung cancer. Cancer Immunol Immunother 2013; 62:1485-97; PMID:23817722; http://dx.doi.org/10.1007/s00262-013-1454-2
   PubMed Web of Science ®Google Scholar
• Mirshahidi S, Kramer VG, Whitney JB, Essono S, Lee S, Dranoff G, Anderson KS, Ruprecht RM. Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: prolonged survival. Vaccine 2009; 27:1825-33; PMID:19201387; http://dx.doi.org/10.1016/j.vaccine.2009.01.089
   PubMed Web of Science ®Google Scholar
• Hernández J, Schoeder K, Blondelle SE, Pons FG, Lone YC, Simora A, Langlade-Demoyen P, Wilson DB, Zaneti M. Antigenicity and immunogenicity of peptide analogues of a low affinity peptide of the human telomerase reverse transcriptase tumor antigen. Eur J Immunol 2004; 34:2331-41; PMID:15259031; http://dx.doi.org/10.1002/eji.200425134
   PubMed Web of Science ®Google Scholar
• Bleeke M, Fest S, Huebener N, Landgraf C, Schraven B, Gaedicke G, Volkmer R, Lode HN. Systematic amino acid substitutions improved efficiency of GD2-peptide mimotope vaccination against neuroblastoma. Eur J Cancer 2009; 45:2915-21; PMID:19695868; http://dx.doi.org/10.1016/j.ejca.2009.07.026
   PubMed Web of Science ®Google Scholar
• Suresh K, Scheid E, Klotz L, Venkateswaran V, Gauldie J, Foley R. Induction of specific human cytotoxic T cells using dendritic cells transduced with an adenovector encoding rat epidermal growth factor receptor 2. Int J Oncol 2011; 39:907-13; PMID:21769423
   PubMed Web of Science ®Google Scholar
• Johnson LE, Frye TP, McNeel DG. Immunization with a prostate cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response. Oncoimmunology 2012; 1:1546-56; PMID:23264901; http://dx.doi.org/10.4161/onci.22564
   PubMed Web of Science ®Google Scholar
• Siegel S, Wagner A, Schmitz N, Zeis M. Induction of anti-tumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model. Br J Haematol 2003; 122:911-4; PMID:12956760; http://dx.doi.org/10.1046/j.1365-2141.2003.04535.x
   PubMed Web of Science ®Google Scholar
• Becker JC, Andersen MH, Hofmeister-Müller V, Wobser M, Frey L, Sandig C, Walter S, Singh-Jasuja H, Kampgen E, Opitz A, et al. Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma. Cancer Immunol Immunother 2012; 61:2091-103; PMID:22565484; http://dx.doi.org/10.1007/s00262-012-1266-9
   PubMed Web of Science ®Google Scholar
• Pedroza-Roldan C, Charles-Niño C, Saavedra R, Govezensky T, Vaca L, Avaniss-Aghajani E, Gevorkian G, Manoutcharian K. Variable epitope library-based vaccines: shooting moving targets. Mol Immunol 2009; 47:270-82; PMID:19853920; http://dx.doi.org/10.1016/j.molimm.2009.09.024
   PubMed Web of Science ®Google Scholar
• Charles-Niño C, Pedroza-Roldan C, Viveros M, Gevorkian G, Manoutcharian K. Variable epitope libraries: new vaccine immunogens capable of inducing broad human immunodeficiency virus type 1-neutralizing antibody response. Vaccine 2011; 29:5313-21; PMID:21600948; http://dx.doi.org/10.1016/j.vaccine.2011.05.007
   PubMed Web of Science ®Google Scholar
• Pulaski, BA and Ostrand-Rosenberg, S. 2001. Mouse 4T1 Breast Tumor Model. Current Protocols in Immunology. 39:20.2:20.2.1–20.2.16.
   Google Scholar
• Bielas JH, Loeb KR, Rubin BP, True LD, Loeb LA. Human cancers express a mutator phenotype. Proc Natl Acad Sci U S A 2006; 103:18238-42; PMID:17108085; http://dx.doi.org/10.1073/pnas.0607057103
   PubMed Web of Science ®Google Scholar
• Fox EJ, Prindle MJ, Loeb LA. Do mutator mutations fuel tumorigenesis? Cancer Metastasis Rev 2013; 32:353-61; PMID:23592419; http://dx.doi.org/10.1007/s10555-013-9426-8
   PubMed Web of Science ®Google Scholar
• Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wolfel C, Huber C, Wolfel T. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A 2005; 102:16013-8; PMID:16247014; http://dx.doi.org/10.1073/pnas.0500090102
   PubMed Web of Science ®Google Scholar
• Segal NH, Parsons DW, Peggs KS, Velculescu V, Kinzler KW, Vogelstein B, Allison JP. Epitope landscape in breast and colorectal cancer. Cancer Res 2008; 68:889-92; PMID:18245491; http://dx.doi.org/10.1158/0008-5472.CAN-07-3095
   PubMed Web of Science ®Google Scholar
• Castle JC, Kreiter S, Diekmann J, Löwer M, van de Roemer N, de Graaf J, Selmi A, Diken M, Boegel S, Paret C, et al. Exploiting the mutanome for tumor vaccination. Cancer Res 2012; 72:1081-91; PMID:22237626; http://dx.doi.org/10.1158/0008-5472.CAN-11-3722
   PubMed Web of Science ®Google Scholar
• Guevara-Patiño JA, Engelhorn ME, Turk MJ, Liu C, Duan F, Rizzuto G, Cohen AD, Merghoub T, Wolchok JD, Houghton AN. Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. J Clin Invest 2006; 116:1382-90; PMID:16614758; http://dx.doi.org/10.1172/JCI25591
   PubMed Web of Science ®Google Scholar
• Engelhorn ME, Guevara-Patiño JA, Noffz G, Hooper AT, Lou O, Gold JS, Kappel BJ, Houghton AN. Autoimmunity and tumor immunity induced by immune responses to mutations in self. Nat Med 2006; 12:198-206; PMID:16444264; http://dx.doi.org/10.1038/nm1363
   PubMed Web of Science ®Google Scholar
• Jaini R, Kesaraju P, Johnson JM, Altuntas CZ, Jane-Wit D, Tuohy VK. An autoimmune-mediated strategy for prophylactic breast cancer vaccination. Nat Med 2010; 16:799-803; PMID:20512124; http://dx.doi.org/10.1038/nm.2161
   PubMed Web of Science ®Google Scholar
• Altuntas CZ, Jaini R, Kesaraju P, Jane-wit D, Johnson JM, Covey K, Flask CA, Dutertre M, Picard JY, Tuohy VK. Autoimmune mediated regulation of ovarian tumor growth. Gynecol Oncol 2012; 124:98-104; PMID:22004903; http://dx.doi.org/10.1016/j.ygyno.2011.09.023
   PubMed Web of Science ®Google Scholar
• Philip M, Schietinger A, Schreiber H. Ribosomal vs. non-ribosomal cellular antigens: factors determining efficiency of indirect presentation to CD4+ T cells. Immunology 2010; 130:494-503; PMID:20331471; http://dx.doi.org/10.1111/j.1365-2567.2010.03258.x
   PubMed Web of Science ®Google Scholar
• Li Y, Wang LX, Pang P, Cui Z, Aung S, Haley D, Fox BA, Urba WJ, Hu HM. Tumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy. Clin Cancer Res 2011; 17:7047-57; PMID:22068657; http://dx.doi.org/10.1158/1078-0432.CCR-11-0951
   PubMed Web of Science ®Google Scholar
• Kedzierska K, Guillonneau C, Gras S, Hatton LA, Webby R, Purcell AW, Rossjohn J, Doherty PC, Turner SJ. Complete modification of TCR specificity and repertoire selection does not perturb a CD8+ T cell immunodominance hierarchy. Proc Natl Acad Sci U S A 2008; 105:19408-13; PMID:19047637; http://dx.doi.org/10.1073/pnas.0810274105
   PubMed Web of Science ®Google Scholar
• Vezys V, Yates A, Casey KA, Lanier G, Ahmed R, Antia R, Masopust D. Memory CD8 T-cell compartment grows in size with immunological experience. Nature 2009; 457:196-9; PMID:19005468; http://dx.doi.org/10.1038/nature07486
   PubMed Web of Science ®Google Scholar